-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.4%
Silverback Therapeutics (NASDAQ:SBTX) Shares Up 3.4%
Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) shares shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.44. 115,799 shares traded hands during trading, a decline of 70% from the average session volume of 383,529 shares. The stock had previously closed at $5.26.
Analyst Upgrades and Downgrades
Separately, Stifel Nicolaus dropped their price objective on Silverback Therapeutics from $6.00 to $5.00 in a report on Friday, May 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $33.00.
Get Silverback Therapeutics alerts:Silverback Therapeutics Trading Up 3.4 %
The firm has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $4.02. The stock has a market cap of $192.98 million, a PE ratio of -2.12 and a beta of 0.65.
Institutional Trading of Silverback Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of SBTX. Acadian Asset Management LLC purchased a new position in shares of Silverback Therapeutics during the 4th quarter valued at about $522,000. Bailard Inc. bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $213,000. Ensign Peak Advisors Inc bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $2,730,000. Schroder Investment Management Group grew its position in Silverback Therapeutics by 3.2% during the 4th quarter. Schroder Investment Management Group now owns 161,173 shares of the company's stock worth $1,073,000 after acquiring an additional 5,037 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Silverback Therapeutics during the 4th quarter worth approximately $77,000. Hedge funds and other institutional investors own 74.89% of the company's stock.About Silverback Therapeutics
(Get Rating)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
See Also
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- PVH Corporation Is On Track For Capital Returns
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) shares shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $5.48 and last traded at $5.44. 115,799 shares traded hands during trading, a decline of 70% from the average session volume of 383,529 shares. The stock had previously closed at $5.26.
银背治疗公司(纳斯达克代码：SBTX-GET评级)的股价在周三午盘交易中飙升3.4%。该公司股价一度高达5.48美元，最新报5.44美元。当日共有115,799股股票成交，较385,529股的平均成交量下降了70%。该股此前收盘价为5.26美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, Stifel Nicolaus dropped their price objective on Silverback Therapeutics from $6.00 to $5.00 in a report on Friday, May 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $33.00.
另外，Stifel Nicolaus在5月13日星期五的一份报告中将Silverback治疗公司的目标价格从6.00美元下调至5.00美元。根据MarketBeat.com的数据，五位股票研究分析师对该股的评级为持有，该公司的平均评级为持有，共识目标价为33.00美元。
Silverback Therapeutics Trading Up 3.4 %
银背治疗公司股价上涨3.4%
The firm has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $4.02. The stock has a market cap of $192.98 million, a PE ratio of -2.12 and a beta of 0.65.
该公司的50日简单移动均线切入位在4.78美元，200日简单移动均线切入位在4.02美元。该股市值为1.9298亿美元，市盈率为-2.12，贝塔系数为0.65。
Institutional Trading of Silverback Therapeutics
银背疗法的制度性交易
About Silverback Therapeutics
关于银背治疗公司
(Get Rating)
(获取评级)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Silverback Treateutics，Inc.是一家生物制药公司，开发组织靶向疗法，用于治疗慢性病毒感染、癌症和其他严重疾病。该公司提供SBT8230来治疗慢性乙肝病毒感染，方法是通过靶向肝脏的TLR8激活来激发抗病毒免疫反应。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- PVH Corporation Is On Track For Capital Returns
- 免费获取StockNews.com关于银背疗法(SBTX)的研究报告
- 世界摔跤娱乐公司准备被出售了吗？
- 3种可能在你的观察名单上获得一席之地的材料类股
- CrowdStrike股价回落，盈利超出预期
- 这些机构会在安巴雷拉入股抄底吗？
- PVH公司有望实现资本回报
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《银背治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Silverback Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧